Age related macular degeneration, pathologic myopic macular degeneration, choroidal neovascularization, central serous chorioretinopathy, diabetic macular edema, etc.
Conditions
Interventions
Retinal disease eye (Fundus diseases):None
Normal group (Without fundus diseases):None
Sponsors
The Zhongshan Ophthalmic Center,Sun Yat-sen University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1.Retinal disease eye: Criteria for the participant eye: 1. Age: =18 years old. 2. At least one eye meets the criteria for the study eye. 3. The patient does not have any other systemic diseases that could affect the status of the retina. 4. The patient does not have dementia, intellectual disability, or other psychiatric conditions that could impair their ability to cooperate with the examination, nor do they have systemic diseases that could compromise their safety. 5. The patient has the capacity and willingness to provide informed consent. Criteria for the Study Eye: 1. Patients with a definitive diagnosis of macular disease, including age-related macular degeneration (AMD), diabetic retinopathy (DR), central serous chorioretinopathy (CSC), pathologic myopia, etc. The diagnosis should be made by a specialist in ocular fundus diseases or a higher-level physician based on diagnostic criteria for ocular fundus diseases (see the section on diagnostic criteria for cases below for details). 2. Best-corrected visual acuity (BCVA) better than 0.7 (logMAR). The diagnosis of the ocular fundus disease .in the study eye should be a single condition. 2.Normal Control Eye: Criteria for the participant eye: 1. Age = 18 years old; 2. At least one eye meets the study eye criteria; 3. Participants are able and willing to provide informed consent. Criteria for the Study Eye: 1. The eye does not contain any diagnosis of ocular disease; 2. BCVA is better than 0 (logMar); 3. The determination of normal eyes is made by doctors with ophthalmology expertise or above.
Exclusion criteria
Exclusion criteria: 1.Retinal disease eye: Criteria for the participant eye: 1. The researcher believes that the patient is not suitable for participating in this clinical trial due to other reasons (such as unstable systemic condition, blood pressure and blood sugar, severe cardiovascular disease, kidney disease, etc.); 2. Blood pressure>180/110mmHg (systolic blood pressure>180mmHg or diastolic blood pressure>110). If the blood pressure can be controlled below this standard after taking antihypertensive drugs, then they can be considered for inclusion; 3. Myocardial infarction or other heart disease requiring hospitalization, cerebral infarction, transient ischemia, acute heart failure within 4 months of enrollment; 4. Women of childbearing potential (i.e., currently pregnant, breastfeeding, or planning to become pregnant within the next year). Women who are potential study participants should be asked about the possibility of pregnancy; Criteria for the Study Eye: 1. The affected eye may have undergone major eye surgery in the past 4 months or in the next 6 months (such as intraocular injections, eye laser or cryotherapy, eyelid surgery, corneal surgery, glaucoma surgery, cataract surgery, vitreoretinal surgery, scleral buckling, etc.); 2. The affected eye has other eye diseases that may affect retinal observation and retinal status, such as any disease that can cause refractive media opacities (if there are no other eye diseases, simple cataracts can cause visual acuity less than 0.5), uveitis, uncontrollable glaucoma, severe extraocular infections such as conjunctivitis, blepharitis, etc. 2.Normal control eyes: Criteria for the participant eye: 1. Participants have other systemic diseases that may affect the retinal status, or take drugs that affect retinal function or retinal toxicity, and do not systematically use corticosteroids greater than 10 mg/day or have systemic diseases that affect life safety; 2. Participants have mental illnesses such as dementia and intellectual disability that affect cooperation with the examination. Criteria for the Study Eye: Eye surgery or intraocular injection, eye laser or cryotherapy within 4 months of the examination eye, including eyelid surgery, corneal surgery, glaucoma surgery, cataract surgery, vitreoretinal surgery, etc.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Subjective metamorphopsia assessment using the traditional paper-based Amsler chart;metamorphopsia area assessment;Quantification of the degree of metamorphosis;Eye movement parameters;NEI VFQ-25 chart;Variation morphology classification; | — |
Secondary
| Measure | Time frame |
|---|---|
| Longitudinal change of morphology change;The correlation of electronic amsler chart with OCT/OCTA;Patient's subjective feelings; | — |
Countries
China
Contacts
Public Contactzhengyingfeng
The Zhongshan Ophthalmic Center,Sun Yat-sen University
Outcome results
None listed